Drug General Information
Drug ID
D0Q5KZ
Former ID
DNCL002566
Drug Name
SGI110
Indication Acute myeloid leukemia; Myelodysplastic syndrome [ICD9: 205, 238.7; ICD10:C92.0, D46] Phase 3 [525074]
Company
Astex Pharmaceuticals
Structure
Download
2D MOL
Target and Pathway
Target(s) DNMT1 Target Info Modulator [533185]
KEGG Pathway Cysteine and methionine metabolism
Metabolic pathways
MicroRNAs in cancer
Pathway Interaction Database Regulation of retinoblastoma protein
PathWhiz Pathway Methionine Metabolism
Reactome PRC2 methylates histones and DNA
NoRC negatively regulates rRNA expression
DNA methylation
WikiPathways Trans-sulfuration and one carbon metabolism
Retinoblastoma (RB) in Cancer
One Carbon Metabolism
Trans-sulfuration pathway
References
Ref 525074ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health.
Ref 533185Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.